Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
8 Dec 2017
Change (% chg)

$0.02 (+1.14%)
Prev Close
$1.75
Open
$1.75
Day's High
$1.83
Day's Low
$1.75
Volume
235,472
Avg. Vol
404,174
52-wk High
$4.09
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €235.33
Shares Outstanding(Mil.): 156.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 57.47 15.67
EPS (TTM): -- -- --
ROI: -- 13.36 34.62
ROE: -- 20.03 16.00

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

Nov 07 2017

BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted

* Antares pharma receives complete response letter from the fda for Xyosted

Oct 20 2017

BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​

Oct 12 2017

BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

* Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

Oct 10 2017

BRIEF-Antares Pharma entered sales agreement with cowen and co to offer, sell shares of its common stock, par value $0.01/share- SEC Filing

* Antares Pharma-on Aug 11,entered sales agreement with Cowen and Company under which co may offer, sell shares of its common stock,par value $0.01/share

Aug 11 2017

BRIEF-Antares Pharma Q2 loss per share $0.02

* Antares pharma reports second quarter 2017 operating and financial results

Aug 08 2017

Competitors

Earnings vs. Estimates

No consensus analysis data available.